CoChat

Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States

Open access

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index; 10 of the 28 sources its claims cite were checked for support.

Abstract

BACKGROUND AND OBJECTIVE: Gene therapies for sickle cell disease (SCD) may offer meaningful benefits for patients and society. This study evaluated the cost-effectiveness of lovotibeglogene autotemcel (lovo-cel), a one-time gene therapy administered via autologous hematopoietic stem cell transplantation, compared with common care for patients in the United States (US) with SCD aged ≥ 12 years with ≥ 4 vaso-occlusive events (VOEs) in the past 24 months. METHODS: We developed a patient-level simulation model accounting for lovo-cel and SCD-related events, complications, and mortality over a lifetime time horizon. The pivotal phase 1/2 HGB-206 clinical trial (NCT02140554) served as the basis for lovo-cel efficacy and safety. Cost, quality-of-life, and other clinical data were sourced from HGB-206 data and the literature. Analyses were conducted from US societal and third-party payer perspectives. Uncertainty was assessed through probabilistic sensitivity analysis and extensive scenario analyses. RESULTS: Patients treated with lovo-cel were predicted to survive 23.84 years longer on average (standard deviation [SD], 12.80) versus common care (life expectancy, 62.24 versus 38.40 years), with associated discounted patient quality-adjusted life-year (QALY) gains of 10.20 (SD, 4.10) and direct costs avoided of $1,329,201 (SD, $1,346,446) per patient. Predicted societal benefits included discounted caregiver QALY losses avoided of 1.19 (SD, 1.38) and indirect costs avoided of $540,416 (SD, $262,353) per patient. Including lovo-cel costs ($3,282,009 [SD, $29,690] per patient) resulted in incremental cost-effectiveness ratios of $191,519 and $124,051 per QALY gained from third-party payer and societal perspectives, respectively. In scenario analyses, the predicted cost-effectiveness of lovo-cel also was sensitive to baseline age and VOE frequency and to the proportion of patients achieving and maintaining complete resolution of VOEs. CONCLUSIONS: Our analysis of lovo-cel gene therapy compared with common care for patients in the US with SCD with recurrent VOEs estimated meaningful improvements in survival, quality of life, and other clinical outcomes accompanied by increased overall costs for the health care system and for broader society. The predicted economic value of lovo-cel gene therapy was influenced by uncertainty in long-term clinical effects and by positive spillover effects on patient productivity and caregiver burden.

Overview

CoChat Summary

## TL;DR

This study modeled the lifetime cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) versus common care for US patients aged ≥12 years with sickle cell disease and ≥4 vaso-occlusive events in the prior 24 months. It found large predicted survival and quality-of-life gains, but at high upfront cost, with incremental cost-effectiveness ratios of $191,519/QALY from a third-party payer perspective and $124,051/QALY from a societal perspective.

## Key findings

  • In the base case, lovo-cel was predicted to increase life expectancy by 23.84 years on average, with survival of 62.24 versus 38.40 years for common care.
  • Discounted QALY gains were 10.20 per patient, and direct costs avoided were $1,329,201 per patient.
  • From the societal perspective, lovo-cel was predicted to avoid 1.19 caregiver QALYs lost and $540,416 in indirect costs per patient.
  • Total lovo-cel-related costs were estimated at $3,282,009 per patient; resulting ICERs were $191,519/QALY (third-party payer) and $124,051/QALY (societal).
  • At a willingness-to-pay threshold of $150,000/QALY, net monetary benefit was negative from the third-party payer perspective (−$423,347) and positive from the societal perspective ($295,445).
  • Scenario analyses showed results were most sensitive to baseline age, VOE frequency, and the proportion of patients achieving and maintaining complete VOE resolution (VOE-CR).

## Methods

  • Patient-level simulation cost-effectiveness model with a lifetime horizon, comparing each simulated patient twice: once with common care and once with lovo-cel.
  • Target population matched HGB-206 TPVOE criteria: age ≥12 years with ≥4 VOEs in the prior 24 months; modeled cohort size was 2,500 patients.
  • Efficacy/safety came primarily from the pivotal phase 1/2 HGB-206 trial; costs, utilities, and other parameters came from HGB-206 data and the literature; analyses used US third-party payer and societal perspectives.
  • Main analyses included base-case ICERs per QALY, plus probabilistic sensitivity analysis, targeted scenario analyses, and one-way sensitivity analyses.

## Limitations

  • The paper states that the target population was aligned with the HGB-206 trial, but real-world patients may differ in baseline age, SCD severity, and comorbidity profile.
  • It states that longer-term data are needed to confirm lifetime impact, because HGB-206 follow-up extends only to 61 months after transplantation.
  • It states that results are sensitive to uncertainty in achieving and maintaining VOE-CR and to simplifying assumptions in the common care arm; this is evident from the text’s reliance on constant hydroxyurea/transfusion use and exclusion of common-care-specific adverse events such as iron overload.
  • Evident from the model description: the analysis assumes benefits persist for life in the base case and does not model fertility impacts of SCD or myeloablative conditioning, except fertility preservation costs.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40273-024-01385-9

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Model structure. Hb hemoglobin, HU hydroxyurea, SCD sickle cell disease, VOC vaso-occlusive crisis, VOE vaso-occlusive event, VOE-CR complete resolution of vaso-occlusive events. a Number of each event per year sampled from annual incidence rates that vary over time. b Timing of incidence for each complication sampled from cumulative complication-free survival curves that are updated each year based on annual development probabilities. c Timing of death sampled from cumulative survival curves that are updated each year based on annual mortality risks
Fig. 1 Model structure. Hb hemoglobin, HU hydroxyurea, SCD sickle cell disease, VOC vaso-occlusive crisis, VOE vaso-occlusive event, VOE-CR complete resolution of vaso-occlusive events. a Number of each event per year sampled from annual incidence rates that vary over time. b Timing of incidence for each complication sampled from cumulative complication-free survival curves that are updated each year based on annual development probabilities. c Timing of death sampled from cumulative survival curves that are updated each year based on annual mortality risksCC BY-NC · PubMed Central
Fig. 2 Framework for lovo-cel’s impact on events, complications, and mortality. ACS acute chest syndrome, AVN avascular necrosis, CKD chronic kidney disease, Hb hemoglobin, HF heart failure, PH pulmonary hypertension, SCD sickle cell disease, VOE vaso-occlusive event, VOE-CR complete resolution of vaso-occlusive events, VTE venous thromboembolism. aThe VOE definition in HGB-206 clinical trial protocol also included acute hepatic sequestration. This event was not included in the analysis due to a lack of supporting evidence in the SCD clinical literature (see Supplementary Information for additional details)
Fig. 2 Framework for lovo-cel’s impact on events, complications, and mortality. ACS acute chest syndrome, AVN avascular necrosis, CKD chronic kidney disease, Hb hemoglobin, HF heart failure, PH pulmonary hypertension, SCD sickle cell disease, VOE vaso-occlusive event, VOE-CR complete resolution of vaso-occlusive events, VTE venous thromboembolism. aThe VOE definition in HGB-206 clinical trial protocol also included acute hepatic sequestration. This event was not included in the analysis due to a lack of supporting evidence in the SCD clinical literature (see Supplementary Information for additional details)CC BY-NC · PubMed Central
Fig. 3 Predicted survival and age at death distributions
Fig. 3 Predicted survival and age at death distributionsCC BY-NC · PubMed Central
Fig 4 Predicted chronic complication development. AVN avascular necrosis, CKD chronic kidney disease, PH pulmonary hypertension
Fig 4 Predicted chronic complication development. AVN avascular necrosis, CKD chronic kidney disease, PH pulmonary hypertensionCC BY-NC · PubMed Central
Fig. 5 Probabilistic sensitivity analysis results. PSA probabilistic sensitivity analysis, QALY quality-adjusted life-year, WTP willingness-to-pay
Fig. 5 Probabilistic sensitivity analysis results. PSA probabilistic sensitivity analysis, QALY quality-adjusted life-year, WTP willingness-to-payCC BY-NC · PubMed Central

Verification

Claims the paper makes

10 Valid · 0 Not valid · 9 Not checked · 67 Own results and interpretations

45 more claims

Create a free account to see all 86 claims and to verify the 3 references still open.

See all claims — free account
  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 23

Create a free account to see these claims.

Citations

Cites

Research works printed but not linked: 4

  1. bluebird bio. bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for patients with sickle cell disease (SCD) 12 years and older with a history of vaso-occlusive events. 2023. https://www.businesswire.com/news/home/20230621695509/en/. Accessed 30 Aug 2023.
  2. Beaudoin F, Thokala P, Nikitin D, Campbell J, Spackman E, McKenna A, et al. Gene therapies for sickle cell disease: effectiveness and value; draft evidence report. Institute for Clinical and Economic Review. 2023. https://icer.org/wp-content/uploads/2023/04/SCD_FOR-PUBLICATION.pdf. Accessed 2 Aug 2023.
  3. Institute for Clinical and Economic Review. 2020–2023 value assessment framework. 2020. https://icer-review.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_102220.pdf. Accessed 29 Oct 2020.
  4. Wenzl M, Chapman S. Performance-based managed entry agreements for new medicines in OECD countries and EU member states. 2019. https://www.oecd-ilibrary.org/content/paper/6e5e4c0f-en. Accessed 8 Feb 2024.

Cited by

See all 18

Metadata

Authors
Herring, W. L., Gallagher, M. E., Shah, N., Morse, K., Mladsi, D., Dong, O. M., Chawla, A., Leiding, J. W., Zhang, L., Paramore, C., & Andemariam, B.
Affiliations
  • Karolinska Institutet (SE)
  • Bluebird Bio (United States) (US)
  • Duke University (US)
  • Columbia University (US)
  • RTI Health Solutions (US)
  • UConn Health (US)
Corresponding author
Herring, William L.
Venue
PharmacoEconomics
Published
2024-04-29
Volume
42
Issue
6
Pages
693-714
ISSN
  • 1170-7690 (ISSN-L)
  • 1179-2027
OpenAlex
W4396212871
Cited by
18
References
65
Citations by year
2026: 7 · 2025: 10 · 2024: 1
FWCI
5.05
Type
journal article
Language
en
Open access
Licence
Locations
  • PharmacoEconomics (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
bluebird bio
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
sickle cell disease, gene therapy, cost-effectiveness, vaso-occlusive events, autologous stem cell transplantation, quality-adjusted life years, life expectancy, societal perspective, third-party payer perspective, caregiver burden, indirect costs, United States health care system
MeSH terms
Adolescent, Adult, Anemia, Sickle Cell, Child, Cost-Benefit Analysis, Female, Humans, Male, Middle Aged, Quality of Life, Recurrence, United States, Genetic Therapy, Hematopoietic Stem Cell Transplantation, Models, Economic, Quality-Adjusted Life Years, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.